Maintenance TKI therapy ‘feasible’ for high-risk CML patients after allogeneic HSCT
Patients with high-risk chronic myeloid leukaemia who undergo allogeneic haematopoietic stem cell transplantation may benefit from continuing with tyrosine kinase inhibitor therapy, US clinicians believe.
Source: MedWire News - Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news
More News: Chronic Leukemia | Chronic Myeloid Leukaemia | Health | Leukemia | Stem Cell Therapy | Stem Cells | Transplants